Objective: To determine the effects of recombinant equine IL-1 and a number of antiinflammatory compounds on the expression and activity of inducible nitric oxide synthase (iNOS) in cultured equine chondrocytes.
Introduction
Osteoarthritis (OA) is a well-known and expensive problem for the equine athlete that causes substantial morbidity in the form of lameness which may seriously curtail the quality of life and athletic serviceability of affected horses. The hallmark of the disease is the degeneration of articular cartilage, a highly specialized tissue consisting of relatively few cells but having a rich extracellular matrix composed of collagens and proteoglycans. Contrary to earlier beliefs, it is now known that articular cartilage is a metabolically active tissue and that chondrocytes are capable of both synthesizing and digesting matrix macromolecules, thus providing a means for maintaining the cartilage matrix in a healthy state. Under normal circumstances, there is an equilibrium between matrix deposition and degradation, however this equilibrium is disrupted in OA leading to the excessive digestion of matrix and progressive loss of important matrix components 1, 2 . Several influences are believed to be responsible for this imbalance in chondrocyte metabolism in OA, and proinflammatory cytokines appear to be among the most important. For example, interleukin-1 (IL-1) causes reduced chondrocyte synthesis of aggrecan and encourages a change in chondrocyte collagen synthesis from a cartilagenous (type II) to a fibrous tissue form (type I) 3 . In addition to their deleterious influence on matrix synthesis in cartilage, IL-1 and other proinflammatory mediators accelerate the degradation of the matrix by inducing the synthesis of proteolytic enzymes, the most important of which are believed to be the matrix metalloproteinases (MMPs).
An inflammatory mediator presently undergoing intense study is nitric oxide (NO). This highly reactive, cytotoxic free radical is a by-product of the oxidation of L-arginine to citrulline, catalyzed by a group of enzymes called NO synthases (NOS). Nitric oxide synthases exist in a number of forms and in a wide array of tissues. It has been shown that there are constitutive forms of NOS (cNOS) responsible for continuous low levels of synthesis and inducible forms (iNOS) which produce large amounts of the mediator when cells expressing this enzyme are activated by mediators such as endotoxins and other bacterial products, and cytokines [4] [5] [6] .
Accumulating evidence supports a role for NO in the arthritic process and its lesions. Early evidence for the involvement of this mediator in rheumatic diseases was the observation that nitrite, a stable end-product of NO, was found in elevated concentrations in the synovial fluid and serum of rheumatoid arthritis patients 7 . Moreover, osteoarthritic cartilage spontaneously produces NO, probably reflecting the in vivo stimulation of chondrocytes by cytokines [8] [9] [10] . It appears that the important quantities of NO liberated in arthritic joints are mainly of chondrocytic origin [8] [9] [10] [11] [12] , and chondrocytes in superficial cartilage layers are a particularly rich source of the molecule 13 . Nitric oxide is hypothesized to contribute to a number of the deleterious influences of IL-1 on cartilage metabolism including augmented expression and activation of MMPs 14, 15 , and reduced synthesis of the natural receptor antagonist protein for IL-1 10 . Accumulating evidence also implicates NO in the inhibition of chondrocyte synthetic activities that occur in OA. Specifically, proteoglycan and type 2 collagen synthesis are inhibited under conditions conducive to NO formation [16] [17] [18] [19] . In models of inflammatory arthritis, treatment with compounds that directly or indirectly inhibit iNOS activity have been shown to reduce the severity of lesions [20] [21] [22] . Similarly, in an established canine OA model, treatment with N-iminoethyl-L-lysine, a selective inhibitor of iNOS, resulted in a significant reduction of arthritis lesions of cartilage and synovial membrane 23 . Moreover, treated dogs had significantly reduced MMP activity in cartilage extracts, paralleled by a reduced immunostaining of chondrocytes for stromelysin 1 and collagenase 1, in addition to reduced concentrations of IL-1 and NO metabolites in the synovial fluid and tissues 23, 24 . These data suggest that inhibition of NO release may attenuate the progression of OA by reducing MMP synthesis in cartilage. If these effects occur in naturally occurring OA in horses, selective iNOS inhibition could hold considerable promise in therapy for this important disease.
A variety of compounds are commonly used in the symptomatic treatment of equine OA including corticosteroids, non-steroidal antiinflammatory drugs and the putative disease-modifying (chondroprotective) agents such as hyaluronan and polysulfated glycosaminoglycan. Recent studies, using cartilage or chondrocytes from a number of species, have demonstrated that each of the above compounds, including corticosteroids, have certain cartilage-sparing properties. For example, at low doses, corticosteroids are capable of reducing cartilage degradation, ostensibly by inhibiting the synthesis of matrix metalloproteinases and cytokines 25, 26 . Similarly, phenybutazone and hyaluronan have been shown to reduce matrix loss from cartilage explants in culture 27, 28 . Polysulfated glycosaminoglycans have been proposed as putative diseasemodifying treatment, initially attributed to anabolic effects on cartilage metabolism 29 . Subsequent experiments using normal and mildly osteoarthritic equine cartilage failed to support substantial effects on aggrecan synthesis and beneficial effects of polysulfated glycosaminoglycans are currently regarded as largely due to reduced proteolytic enzyme activity [30] [31] [32] . While often effective in reducing lameness, and possessing at least some cartilage sparing potential, the specific roles of these and other medications in retarding the progression of OA lesions remains unclear. While continued efforts are being directed at studying the role of these drugs in modulating the pathophysiologic processes of equine OA, there remains uncertainty regarding their precise mechanisms of action. A potential means by which some or all of these compounds may provide symptomatic relief and/or chondroprotection or both may be by modifying the synthesis or actions of NO.
The purpose of the study presented here was to characterize the expression of equine iNOS in chondrocytes in stationary culture and to determine if iNOS expression or activity or both are influenced by commonly prescribed antiarthritis compounds in short-term reIL-1 -stimulated cultures.
Materials and methods

TISSUE SOURCES AND CELL CULTURE
Grossly normal metacarpophalangeal articular cartilage was obtained from adult horses (2-8 years) sacrificed for reasons other than musculoskeletal disease. Cartilage was dissected from the subchondral bone, and chondrocytes were isolated by sequential digestion with pronase and collagenase as previously described, with minor modifications 25 . High density monolayer cultures were established in Dulbecco's modified Eagle's medium, with 10% fetal bovine serum and penicillin and streptomycin under standard culture conditions. Experiments were performed using first-passage, high-density cultures.
EXTRACTION OF RNA AND CDNA SYNTHESIS
Total RNA was extracted, using a commercial extraction preparation* and following the manufacturer's instructions. Briefly, this agent was added to each well after washing the cells with cold phosphate-buffered saline solution (PBS) and, after an incubation of 5 min at 25°C, the solution was transferred to centrifuge tubes to which was added chloroform (0.2 ml/ml of base reagent), followed by vigorous agitation and a second incubation (10 min, 22°C). After centrifugation (12,000×g, 4°C), the aqueous phase was removed and the RNA was precipitated with isopropanol, then the pellet was washed with 75% ethanol. The RNA was re-centrifuged and the pellet was resuspended in diethyl pyrocarbonate treated sterile water and quantified spectrophotometrically.
AMPLIFICATION OF CDNA AND PROBE PREPARATION AND
SEQUENCING
Complementary DNA was synthesized, using reverse transcriptase-polymerase chain reaction (RT-PCR) with 2 g of total RNA from a chondrocyte culture that had been stimulated (6 h) with recombinant equine IL-1 at 10 ng/ml. A specific set of oligonucleotide primers for the iNOS gene were synthesized on the basis of the published human and rodent iNOS cDNA sequences 33, 34 and was used at a final concentration of 3 pM/ l. The sequences for the iNOS primers were 5′-GTT CCC CCA GCG GAG TGA-3′ (sense primer), starting at position 738 bp of the published sequence of the human gene, and 5′-TCT TTC CAG AGG GAG GCC A-3′ (antisense primer) and ending at position 1235 bp. Amplification by PCR produced 497 bp cDNA fragment of the putative iNOS gene, which, after purification, was directionally ligated directly to pBluescriptSK±vector. An RNA probe was produced from the clone *Trizol Reagent, Gibco BRL, Grand Island, NY. 
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using T3 RNA polymerase to incorporate digoxigenin-11-dUTP.* Sequencing of the probe was performed using manual methods.
NORTHERN BLOT HYBRIDIZATION
Northern blot hybridization was conducted as previously described 25 . Total chondrocyte RNA was resolved on 1.2% agarose-formaldehyde gels, using 4 g of RNA. After overnight transfer to nylon membranes, † RNA was cross-linked to the membranes by exposure to UV light. After prehybridization (1 h, 68°C) in a saline-sodium citrate-based (SSC) buffer, the membranes were hybridized overnight at 68°C in 35 ng of labeled probe/ml. Serial post-hybridization washes were carried out at 68°C, with decreasing concentrations of SSC buffer, followed by brief washing in a maleic acid buffer. Detection was accomplished, using a chemiluminescent method with digoxigenin-11-uridyl triphosphate and Lumigen (4-methoxy-4-(3-phophatephenyl)spiro-1,2-dioxetane-3,2′-adama ntane (disodium salt) as a substrate for alkaline phosphatase conjugated to digoxygenin antibody Fab fragments, as described by the manufacturer, with slight modifications. The membranes were then subjected to autoradiography at room temperature for 15 min. Autoradiographic films were scanned using a desktop scanner and the intensity of each band was quantified using image acquisition and analysis software to determine relative mRNA abundance. ‡ Standardization against the corresponding values for ethidium bromide-stained 28S ribosomal RNA enabled semiquantitative evaluation of specific mRNA (i.e., expression of iNOS was calculated as the ratio of the intensity of the iNOS bands to the intensity of the 28S rRNA band).
STIMULATION WITH REIL-1
To test the influence of reIL-1 on the expression of iNOS in normal equine chondrocytes, confluent cultures of first passage cells from two horses were grown to confluence in individual six-well plates (1×10 6 cells/well) and were stimulated for 8 h with reIL-1 (0, 1, 5, 10, 50, 100 ng/ml), followed by RNA extraction and Northern blot hybridization. To characterize the temporal aspects of iNOS expression, similar cultures were treated with 10 ng/ml reIL-1 for 0, 2, 4, 6, 8, 12 h, followed by RNA isolation and Northern blot hybridization.
TREATMENT WITH ANTIARTHRITIS COMPOUNDS
Cultures derived from three horses were used in this portion of the study. First-passage chondrocytes, derived from metacarpophalangeal joints with grossly normal articular cartilage were grown to confluence in six-well plates. After a period of 3-5 days of culture under serumfree conditions, each well received one of a number of randomly-assigned treatments consisting of control (no additives); reIL-1 (10 ng/ml) and one of dexamethasone (DEX) (10 −6 M and 10 −5 M), hyaluronan (HA) (10 and 100 g/ml), polysulfated glycosaminoglycan (PSGAG) (10 and 100 g/ml), or phenylbutazone (PBZ) (10 and 100 g/ ml) in the presence and absence of reIL-1 (10 ng/ml) ( Table I) . After 6 h incubation, RNA was extracted for Northern blotting. Conditioned media from similarly treated 24 h cultures, using cartilage from three different animals, were used for the indirect determination of NO. To ensure that treatments did not have cytotoxic effects, a live-dead assessment was conducted on each treatment well of a single culture, using a commercially-available kit following manufacturer's directions. § NITRITE CONCENTRATIONS IN CONDITIONED MEDIA Nitric oxide synthase activity was indirectly determined by measuring the stable end product NO 2 using a spectrophotometric method 35 . Briefly, 200 l aliquots of culture medium were added to an equal volume of a freshly prepared mixture of equal proportions of 1% sulfanilamide and 0.1% naphthylethylenediamine dihydrochloride. The absorbance of the solution was read at 550 nm after a 30 min incubation and NO 2 concentrations were determined using a standard curve.
To investigate the possibility that one or more treatment may have caused a disproportionate synthesis of either nitrite or nitrate by NO, nitrate in conditioned media was converted to nitrite using nitrate reductase in an NADPH system as previously reported 36 . Briefly, 200 l aliquots of culture medium were incubated with NADPH (40 M) and nitrate reductase\ (14 mU) in 20 mM Tris for 15 min (20°C), after which the reaction was terminated by the addition of PSGAG control-1 10 g/ml − 8 PSGAG control-2 100 g/ml − 9 PSGAG-reIL1 10 g/ml + 10 PSGAG-reIL1 100 g/ml + 11
Hyaluronan control-1 10 g/ml − 12
Hyaluronan control-2 100 g/ml − 13
Hyaluronan-reIL1 10 g/ml + 14
Hyaluronan-reIL1 100 g/ml + 15
Phenylbutazone control-1 10 g/ml − 16
Phenylbutazone control-2 100 g/ml − 17
Phenylbutazone-reIL1 10 g/ml + 18
Phenylbutazone-reIL1 100 g/ml + (PSGAG: polysulfated glycosaminoglycan; reIL-1 : recombinant equine interleukin-1 .)
After a period of 3-5 days of culture under serum-free conditions, each well received one of the treatments listed above. After 6 h incubation, RNA was extracted for Northern blotting.
Conditioned media from similarly treated 24 h cultures were used for the indirect determination of NO (Greiss reaction).
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ANALYSIS OF DATA
Comparison of means for relative expression of iNOS as well as media concentrations of nitrite were performed using a two-way ANOVA (blocked by horse) followed by a Dunnett's test. A P value <0.05 was considered significant.
Results
AMPLIFICATION OF CDNA
The 497-bp fragment of equine iNOS amplified by use of RT-PCR cDNA had approximately 88% sequence identity with the human cDNA sequence and 92% identity of the deduced amino acid sequence indicating that the cloned fragment is a portion of the corresponding equine iNOS message. (GenBank accession number AF329377).
STIMULATION WITH REIL-1
Northern blot analysis, using the equine iNOS probe, showed a 4.6 kb positively hybridizing band from activated equine chondrocytes. Subsequent studies indicated a dose-dependent stimulatory effect of reIL-1 on iNOS expression (Fig. 1) . Temporal studies indicated that iNOS expression was rapidly up-regulated by reIL-1 (Fig. 2) .
EFFECTS OF ANTIINFLAMMATORY COMPOUNDS ON INOS
EXPRESSION
Evaluation of cell viability using a calcein/ethidium-based live/dead assay revealed negligible cell death with any treatment combination (data not shown). None of the antiarthritis compounds influenced resting expression of iNOS. DEX, at both 10 −6 and 10 −5 M, markedly reduced reIL-1 -induced up-regulation of iNOS expression (Fig. 3) . A similar effect was observed for PSGAG; this compound also significantly reduced reIL-1 -stimulated iNOS expression at both doses tested (10 and 100 g/ml). Neither HA nor PBZ had a statistically-significant effect on iNOS expression in cytokine-stimulated cultures.
EFFECTS OF ANTI-INFLAMMATORY COMPOUNDS ON INOS ACTIVITY
Nitrate conversion was conducted on media supernatants from a single horse to ensure that disproportionate production of either nitrate or nitrite influenced the indirect determination of NO activity. Because results following nitrate conversion closely paralleled those using nitrite concentration alone, Greiss reaction values (nitrite) on unconverted supernatants were conducted and are reported. Statistical analyses of these data from 24 h cultures paralleled our findings for RNA expression. Specifically, spent media from cultures treated with DEX at both concentrations tested and PSGAG at both 10 and 100 g/ml had nitrite concentrations that were significantly less than those of cytokine-treated controls (Fig. 4) . Cytokine-stimulated cells exposed to HA and PBZ had media nitrite concentrations comparable to reIL-1 -treated controls. (Fig. 4) .
Discussion
While the role of NO in the physiology and pathobiology of equine vascular reactivity and neuromuscular transmission in a number of organ systems has been the subject of recent research, its role in equine OA pathogenesis has received little study. We prepared an RNA probe to characterize an inducible member of the NOS family that corresponds to a similarly-sized cDNA demonstrated in cytokine-stimulated human chondrocytes 37 . Results of subsequent short-term experiments using reIL-1 -stimulated cultures complement previous reports describing NO synthesis by equine chondrocytes in response to stimulation with proinflammatory mediators 11, 38 . We also provide data indicating that chondrocyte iNOS expression and activity are influenced by corticosteroids and polysulfated glycosaminoglycans.
We observed a marked and rapid up-regulation of iNOS expression in chondrocytes by reIL-1 , an event that is hypothesized to contribute to the pathophysiologic events and lesions of OA; however the specific contribution(s) of NO to IL-1-induced cartilage matrix depletion is controversial. Early laboratory studies revealed that the MMP activity in IL-1 and TNF -stimulated bovine and human chondrocyte and explant cultures was enhanced by NO donors in a dose-dependent fashion 15 , an effect that was inhibited in the presence of competitive inhibitors of NOS. Similar -1 (reIL-1) . Total RNA (4 g) was resolved on formaldehyde agarose gels as described in Materials and Methods. Blots were probed with a digoxigenin-labeled iNOS RNA probe. Interleukin-1 concentrations (ng/ml) are given below the corresponding lane. The position of the iNOS message with respect to the rRNA bands is indicated to the right of the iNOS bands. The corresponding ethidium bromide-stained 28S rRNA bands are shown below. Table I . Inducible NOS expression was calculated as the ratio of the intensity of the iNOS bands to the intensity of the ethidium bromide-stained 28S ribosomal RNA band of the electrophoretic gel. Values are mean (±S.E.M.) expression from three experiments. Relative expression of reIL-1 -stimulated iNOS in chondrocytes treated with dexamethasone (10 −6 M and 10 −5 M) and polysulfated glycosaminoglycan (polysulfated GAG) (10 g/ml, and 100 g/ml) (marked by asterisks) was significantly (P<0.05) less than that of reIL-1 -stimulated (positive control) cells. Table I . Values are mean (±S.E.M.) expression from three experiments. Nitrite accumulation in spent media from chondrocytes treated with dexamethasone (10 −6 M and 10 −5 M) and polysulfated glycosaminoglycan (10 g/ml, and 100 g/ml) (marked by asterisks) was significantly (P<0.05) less than that of reIL-1 -stimulated (positive control) cells. comparable rates of proteoglycan depletion to controls 38 , and a protective effect of NO on proteoglycan depletion has been observed in early, but not late, explant cultures of bovine chondrocytes 18, 40 . Apparent disparities in these findings may be due to experimental design, species differences, temporal effects, relative concentrations of NO and cytokines, and the presence or absence of undetected ancillary mediators.
Although the specific molecular and cellular actions and interactions of NO on MMP expression and cartilage degradation remain to be determined, in vivo arthritis models provide important evidence implicating NO in articular pathobiology. For example, a recent study using an inflammatory arthritis model in iNOS-deficient mice revealed that genetically-disrupted mice had reduced proteoglycan depletion as well as fewer cartilaginous lesions and osteophytes than normal mice 41 . Similar findings have been observed using an established canine OA model 23, 24 , supporting a major role for NO in cartilage damage in joint diseases.
Northern blot analyses indicated that expression of our chondrocyte iNOS was inhibited by dexamethasone at 10 −6 -10 −5 M. In other species, a number of isoforms of NOS have been described and vary in their sensitivity to glucocorticoids 29, 42 . Many iNOS isolated from mammalian chondrocytes are insensitive to corticosteroids at modest doses, however, paralleling our findings, bovine iNOS expression is inhibited with high doses of dexamethasone 12 . These findings may suggest a limited influence of endogenous glucocorticoids on iNOS expression but that pharmacologic doses are inhibitory.
PSGAG was observed to reduce reIL-1 -induced expression of iNOS. While polysulfated glycosaminoglycans are generally considered effective for the symptomatic treatment of OA in humans and animals, the mechanism(s) of action of PSGAG in pain relief and disease modification (chondroprotection) remain to be confirmed. Based on our results, it is possible that, in addition to other potential effects, the chondroprotective potential of PSGAG may be due to their ability to inhibit the expression of iNOS. It has been shown that heparinoids are capable of influencing gene expression in connective tissue mesenchyme. A recent report indicates that heparin down-regulates MMP expression in human gingival fibroblasts 43 and it has been shown that heparin and pentosan polysulfate, a sulfated glycosaminoglycan of plant origin, down-regulate phorbolinduced cancer cell proliferation by interfering with the binding of transcription factor to gene promoter AP-1 sites 44 . PSGAG may down-regulate equine iNOS by similar mechanisms. Inhibition of NO synthesis or activity has been recently reported for other putative antiarthritis agents. For example, in acute experiments, glucosamine, an aminomonosaccharide, significantly inhibited NO synthesis by lipopolysaccharide-stimulated equine articular cartilage explants 45 , and doxycycline (a tetracycline derivative) reduces the expression of iNOS in human chondrocytes 46 , providing an potential explanation for the beneficial effects of these compounds in some arthritis models.
Hyaluronan is a glycosaminoglycan composed of the disaccharides D-glucuronic acid and N-acetyl-Dglucosamine. It has been shown to have beneficial effects in the treatment of incipient joint disease in horses and laboratory studies have demonstrated its ability to inhibit matrix degradation in IL-1-activated chondrocytes by mechanisms yet to be determined 28, 47 . In this study, mean relative expression of iNOS in cytokine/hyaluronan treated cultures was approximately half that of the positive (reIL-1 ) controls, however this difference was not statistically significant. It is possible that with greater replication this phenomenon may have approached statistically significance and a potential effect of hyaluronan on iNOS expression cannot be ruled out based on this study. Nevertheless, reIL-1 -stimulated chondrocytes exposed to HA produced nitrite in quantities comparable to reIL-1 controls. This latter finding suggests that, under these experimental conditions, a biologically significant effect of HA on net NO activity was absent. Previous research has indicated that HA may be delayed in its actions and the possibility that a more prolonged exposure to HA may have produced different results remains to be investigated. Nonetheless, HA has been shown to have effects on the synthetic activities of synovial fibroblasts and chondrocytes cultured under similar conditions and with comparable incubation times [47] [48] [49] . Interestingly, of several glucosamine salts tested for inhibitory activity against NO, N-acetyl-Dglucosamine, the hexosamine comprising half the residues of hyaluronan, possessed no such activity in lipopolysaccharide-stimulated equine articular cartilage explants 50 . Experimental results for phenylbutazone were similar effects to those of hyaluronan in this study. Specifically, mean expression in cytokine/PBZ-treated cultures was reduced by nearly half, yet nitrite content in conditioned media was not substantially different. While it appears that phenylbutazone is capable of limiting the proteoglycan depletion that accompanies in vitro cartilage culture 27 , our data suggest that the effect is unlikely to be due to modulation of iNOS synthesis or activity. Limited data is available with respect to the influence of various NSAIDs on iNOS expression, however transcriptional influences of NSAIDs on iNOS expression have been reported. Specifically, rhein and diacerhein have been reported to regulate iNOS mRNA expression in IL-1 -stimulated osteoarthritic human chondrocytes 51 . The identity and precise mechanism(s) of action of various NSAIDs on iNOS synthesis and activity remain to be determined.
In summary, the results of this study provide previously unreported data on the modulation of equine iNOS expression and activity. These data parallel findings reported using tissues from other species, support a role for NO in the pathogenesis of equine OA, and provide new information concerning mechanisms of action of antiarthritis drugs used in horses.
